{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:44:05Z","timestamp":1793169845048,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071472"],"award-info":[{"award-number":["82071472"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901102"],"award-info":[{"award-number":["81901102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to observe the efficacy and safety of rimegepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of vestibular migraine (VM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients meeting the diagnostic criteria for VM or probable VM received rimegepant 75\u00a0mg for acute attacks. They rated the severity of five prominent VM symptoms (vertigo, unsteadiness or dizziness, nausea or vomiting, photophobia or phonophobia, and headache) on a 0\u20133 scale. Assessments were recorded at baseline, 30\u00a0min, 1\u00a0h, 2\u00a0h, 4\u00a0h, 24\u00a0h, and 48\u00a0h post-treatment. Efficacy outcomes included the percentage of patients with symptom recovery (from moderate\/severe to absent\/mild), moderate\/severe symptoms, and freedom from symptoms at various time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>18 VM patients were included. All symptom scores showed a decreasing trend from 30\u00a0min after rimegepant treatment. Scores for all symptoms except headache were significantly decreased at 2\u00a0h. The percentage of patients with moderate\/severe symptoms decreased from 50.0% to 72.2% at baseline to 0% by 24\u00a0h for all symptoms. Moreover, freedom from all symptoms except unsteadiness\/dizziness was achieved by 24\u00a0h. No adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We first demonstrate rimegepant 75\u00a0mg is safe and well-tolerated, which contributes a rapid relief of the prominent symptoms of VM including vertigo, unsteadiness or dizziness, nausea or vomiting, photophobia or phonophobia, and headache. Although required further validation, our findings may provide novel viewpoint on the treatment of VM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41598-026-39902-9","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:17:47Z","timestamp":1771233467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy of rimegepant for the acute treatment of vestibular migraine"],"prefix":"10.1038","volume":"16","author":[{"given":"Heling","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"39902_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-201644","volume":"32","author":"T Lempert","year":"2022","unstructured":"Lempert, T. et al. Vestibular migraine: diagnostic criteria (Update)1. J. Vestib. Res. 32, 1\u20136 (2022).","journal-title":"J. Vestib. Res."},{"key":"39902_CR2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). ;38:1-211.The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018).","DOI":"10.1177\/0333102417738202"},{"key":"39902_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1474-4422(13)70107-8","volume":"12","author":"JM Furman","year":"2013","unstructured":"Furman, J. M., Marcus, D. A. & Balaban, C. D. Vestibular migraine: clinical aspects and pathophysiology. Lancet Neurol. 12, 706\u2013715 (2013).","journal-title":"Lancet Neurol."},{"key":"39902_CR4","doi-asserted-by":"crossref","unstructured":"Hoskin, J. L. & Fife, T. D. New Anti-CGRP medications in the treatment of vestibular migraine. Front. Neurol. ;12. (2022).","DOI":"10.3389\/fneur.2021.799002"},{"key":"39902_CR5","doi-asserted-by":"crossref","unstructured":"Kitamura, S. et al. Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine in Japan: A double-blind, Randomized Controlled Trial (The Journal of Head and Face Pain, 2025).","DOI":"10.1111\/head.15095"},{"key":"39902_CR6","doi-asserted-by":"crossref","unstructured":"Beh, S. C. & Friedman, D. I. Acute vestibular migraine treatment with noninvasive vagus nerve stimulation. Neurology ;93. (2019).","DOI":"10.1212\/WNL.0000000000008388"},{"key":"39902_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s004150050478","volume":"246","author":"M Dieterich","year":"1999","unstructured":"Dieterich, M. & Brandt, T. Episodic vertigo related to migraine (90 cases): vestibular migraine? J. Neurol. 246, 883\u2013892 (1999).","journal-title":"J. Neurol."},{"key":"39902_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/14737175.2024.2405739","volume":"24","author":"EP Calandre","year":"2024","unstructured":"Calandre, E. P., Bassila, C., Slim, M. & Rico-Villademoros, F. An overview of the current and emerging treatment options for vestibular migraine. Expert Rev. Neurother. 24, 1157\u20131179 (2024).","journal-title":"Expert Rev. Neurother."},{"key":"39902_CR9","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","volume":"271","author":"A Lepcha","year":"2013","unstructured":"Lepcha, A., Amalanathan, S., Augustine, A. M., Tyagi, A. K. & Balraj, A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur. Arch. Otorhinolaryngol. 271, 2931\u20132936 (2013).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"39902_CR10","doi-asserted-by":"crossref","unstructured":"Liu, F., Ma, T., Che, X., Wang, Q. & Yu, S. The efficacy of Venlafaxine, Flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front. Neurol. ;8. (2017).","DOI":"10.3389\/fneur.2017.00524"},{"key":"39902_CR11","doi-asserted-by":"crossref","unstructured":"Bayer, O., Adrion, C., Al Tawil, A., Mansmann, U. & Strupp, M. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with Metoprolol (PROVEMIG). Trials 2019;20.","DOI":"10.1186\/s13063-019-3903-5"},{"key":"39902_CR12","doi-asserted-by":"crossref","unstructured":"Staab, J. P. et al. Rizatriptan vs placebo for attacks of vestibular migraine. JAMA Neurol. ;82. (2025).","DOI":"10.1001\/jamaneurol.2025.1006"},{"key":"39902_CR13","doi-asserted-by":"publisher","first-page":"10453","DOI":"10.1523\/JNEUROSCI.3336-13.2014","volume":"34","author":"AE Luebke","year":"2014","unstructured":"Luebke, A. E. et al. Loss of -Calcitonin Gene-Related peptide (CGRP) reduces the efficacy of the Vestibulo-ocular reflex (VOR). J. Neurosci. 34, 10453\u201310458 (2014).","journal-title":"J. Neurosci."},{"key":"39902_CR14","doi-asserted-by":"crossref","unstructured":"Raggi, A. et al. Hallmarks of primary headache: part 1 \u2013 migraine. J. Headache Pain ;25. (2024).","DOI":"10.1186\/s10194-024-01889-x"},{"key":"39902_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo, A. F. & Hay, D. L. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol. Rev. 103, 1565\u20131644 (2023).","journal-title":"Physiol. Rev."},{"key":"39902_CR16","doi-asserted-by":"crossref","unstructured":"Russo, C. V. et al. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study. Cephalalgia ;43. (2023).","DOI":"10.1177\/03331024231161809"},{"key":"39902_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40263-024-01094-z","volume":"38","author":"T Kouga","year":"2024","unstructured":"Kouga, T., Miwa, T., Sunami, K. & Itoh, Y. Effectiveness of Anti-Calcitonin Gene-Related peptide medication in vestibular migraine: A retrospective cohort study in an Asian population. CNS Drugs. 38, 637\u2013648 (2024).","journal-title":"CNS Drugs"},{"key":"39902_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu, S. et al. Safety and efficacy of Rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 22, 476\u2013484 (2023).","journal-title":"Lancet Neurol."},{"key":"39902_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton, R. B. et al. Rimegepant, an oral calcitonin Gene\u2013Related peptide receptor Antagonist, for migraine. N. Engl. J. Med. 381, 142\u2013149 (2019).","journal-title":"N. Engl. J. Med."},{"key":"39902_CR20","doi-asserted-by":"crossref","unstructured":"Yu, S. et al. Rimegepant orally disintegrating tablet 75\u00a0mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial. J. Headache Pain ;25. (2024).","DOI":"10.1186\/s10194-024-01731-4"},{"key":"39902_CR21","doi-asserted-by":"crossref","unstructured":"Iannone, L. F. et al. Effectiveness and tolerability of Rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J. Headache Pain ;26. (2025).","DOI":"10.1186\/s10194-024-01935-8"},{"key":"39902_CR22","doi-asserted-by":"crossref","unstructured":"Wang, J. et al. Patient-reported outcomes of Rimegepant for acute and preventive treatment of migraine in china: a prospective, multicenter, real-world study. J. Headache Pain ;26. (2025).","DOI":"10.1186\/s10194-025-02197-8"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39902-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39902-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39902-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:16:09Z","timestamp":1773825369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39902-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39902"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39902-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors did not receive any medical writing or editorial assistance for this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing"}},{"value":"Ethical approval was granted by the Ethics Committee of Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"9247"}}